Business
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
SAN CARLOS, Calif., May 07, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.
About this update from Beone Medicines Ltd. Class A
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1650,"height":310,"url":"https://media.zenfs.com/en/business-wire.com/c2528ac65f3420289586c2ca0101f375"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Dns0BtVR4oK7cN_TqHnwbg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c2528ac65f3420289586c2ca0101f375","width":960,"height":180},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/u3nohx8t38JIxwQUKgWWTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00NTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/c2528ac65f3420289586c2ca0101f375","width":1200,"height":225}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First quarter 2025 total revenues increased 49% to $1.1 billion with BRUKINSA® (zanubrutinib) global sales increasing 62% to $792 million on strong demand growth versus first quarter 2024","length":187,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Achieved GAAP profitability and significantly improved operating cash flow","length":74,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Advanced late-stage hematology and solid tumor pipelines with plan to host Investor R&D Day on June 26","length":106,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Secured shareholder approval to rename the Company to BeOne Medicines Ltd. and redomicile to Switzerland","length":104,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":471,"olType":false},{"type":"text","content":"SAN CARLOS, Calif., May 07, 2025--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.","length":268,"tagName":"p"},{"type":"text","content":""We delivered another exceptional quarter, achieving our first quarter of GAAP profitability with continued global revenue growth. In the U.S., BRUKINSA remains the leader in new chronic lymphocytic leukemia (CLL) patient starts across all lines of therapy, and for the first time has become the overall BTKi market share leader," said John V. Oyler, Co-Founder, Chairman, and CEO of BeiGene. "We’ve made signifi...